Valuation: Eisai Co., Ltd.

Market Cap 1,390B 8.85B 7.72B 7.29B 6.62B 12.4B 850B 12.45B 87.32B 33.7B 432B 33.26B 32.52B P/E 2027 *
24.5x
P/E 2028 * 20.5x
Enterprise Value 1,304B 8.31B 7.24B 6.84B 6.21B 11.64B 797B 11.68B 81.93B 31.61B 405B 31.2B 30.51B EV / Sales 2027 *
1.43x
EV / Sales 2028 * 1.34x
Free-Float
94.55%
Yield 2027 *
3.33%
Yield 2028 * 3.28%
1 day-0.46%
1 week+5.84%
Current month+4.01%
1 month+1.92%
3 months+26.35%
6 months+3.48%
Current year+5.79%
1 week 4,671
Extreme 4671
4,990
1 month 4,584
Extreme 4584
4,990
Current year 3,660
Extreme 3660
5,243
1 year 3,660
Extreme 3660
5,276
3 years 3,463
Extreme 3463
8,802
5 years 3,463
Extreme 3463
11,250
10 years 3,463
Extreme 3463
12,765
Manager TitleAgeSince
Chief Executive Officer 78 2003-05-31
Director of Finance/CFO 49 2025-12-31
Chief Tech/Sci/R&D Officer 58 2025-03-31
Director TitleAgeSince
Director/Board Member 78 1983-05-31
Director/Board Member 67 2024-06-13
Director/Board Member 68 2025-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.46%+5.84%-4.48%-44.82% 8.85B
+0.04%+3.34%+53.32%+100.52% 1,028B
-0.09%+1.66%+53.24%+66.45% 651B
-0.02%+2.66%+18.65%+71.97% 466B
-1.22%+3.66%+34.59%+38.81% 346B
-0.79%+2.73%+17.73%+25.11% 266B
+0.58%+6.76%+10.58%+17.75% 259B
+1.55%+2.20%+35.12%+45.91% 208B
+0.79%+1.84%-27.55%-56.48% 191B
-0.52%+4.45%+31.57%+98.11% 186B
Average -0.01%+3.51%+22.28%+36.33% 361.06B
Weighted average by Cap. -0.04%+3.10%+34.75%+61.34%

Financials

2027 *2028 *
Net sales 910B 5.8B 5.05B 4.77B 4.33B 8.12B 556B 8.15B 57.17B 22.06B 283B 21.77B 21.29B 968B 6.16B 5.38B 5.08B 4.61B 8.64B 592B 8.67B 60.8B 23.46B 301B 23.16B 22.64B
Net income 57.08B 364M 317M 299M 272M 509M 34.89B 512M 3.59B 1.38B 17.74B 1.37B 1.34B 67.73B 431M 376M 355M 323M 604M 41.4B 607M 4.26B 1.64B 21.05B 1.62B 1.58B
Net Debt -85.83B -547M -477M -450M -409M -766M -52.46B -769M -5.39B -2.08B -26.67B -2.05B -2.01B -93.33B -595M -518M -490M -445M -833M -57.05B -836M -5.86B -2.26B -29.01B -2.23B -2.18B
Logo Eisai Co., Ltd.
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Employees
10,543
Date Price Change Volume
26-09-18 ¥4,930.00 -0.46% 2,095,500
26-09-17 ¥4,953.00 +3.51% 1,520,400
26-09-16 ¥4,785.00 +0.38% 868,200
26-09-15 ¥4,767.00 +0.51% 864,600
26-09-14 ¥4,743.00 +1.82% 1,043,700
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
4,930.00JPY
Average target price
4,575.00JPY
Spread / Average Target
-7.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4523 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!